Literature DB >> 7532863

Changes induced by sodium cromoglycate on brain serotonin turnover in morphine dependent and abstinent mice.

O San-Martin-Clark1, J C Leza, I Lizasoain, P Lorenzo.   

Abstract

This study was designed to explain the action of sodium cromoglycate (CRO) on the brain serotonergic system in control, morphine tolerant (by SC implantation of a 75 mg morphine pellet), and also in morphine dependent mice just before naloxone-precipitated withdrawal. After SC injections of CRO in control mice, morphine tolerant mice (day 4 of addiction), and 1 h before abstinence (withdrawal was induced by SC injection of 1 mg/kg naloxone on day 4 of addiction), animals were decapitated and various brain areas were rapidly removed. 5HT (Serotonin) and 5HIAA (5-hydroxyindole-3-acetic acid) were measured by high performance liquid chromatography coupled with electrochemical detection (HPLC-ECD). The ratio 5HIAA/5HT provided one index by which the turnover of the indoleamine was measured. CRO increased the turnover of 5HT in most of the brain areas studied in both control and morphine dependent mice. Furthermore, previous administration of CRO prior to naloxone challenge induced a significant increase in the 5HIAA/5HT ratio in the hypothalamus and striatum. These results are discussed as the reason for the preventive effect of CRO on jumping behaviour in morphine abstinent mice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7532863     DOI: 10.1007/bf02245529

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  31 in total

Review 1.  Histaminergic transmission in the mammalian brain.

Authors:  J C Schwartz; J M Arrang; M Garbarg; H Pollard; M Ruat
Journal:  Physiol Rev       Date:  1991-01       Impact factor: 37.312

2.  The role of dopamine and norepinephrine in the naloxone-induced abstinence of morphine-dependent mice.

Authors:  Y Maruyama; A E Takemori
Journal:  J Pharmacol Exp Ther       Date:  1973-06       Impact factor: 4.030

3.  An action of disodium cromoglycate: inhibition of cyclic 3',5'-AMP phosphodiesterase.

Authors:  N Lavin; G S Rachelefsky; S A Kaplan
Journal:  J Allergy Clin Immunol       Date:  1976-01       Impact factor: 10.793

4.  Regulation of intracellular cyclic GMP and cyclic AMP levels in mouse lung fragments by disodium cromoglycate, beta-adrenergic agonists, cholinergic activators, and histamine.

Authors:  J B Moore
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1977-08

5.  Ultrastructural observations on mast cell degranulation and its prevention.

Authors:  M Djaldetti; E van der Lijn; I Notti
Journal:  Nouv Rev Fr Hematol       Date:  1979

6.  Monoamine mediation of the morphine-induced activation of mice.

Authors:  B J Carroll; P T Sharp
Journal:  Br J Pharmacol       Date:  1972-09       Impact factor: 8.739

Review 7.  Neural substrates of opiate withdrawal.

Authors:  G F Koob; R Maldonado; L Stinus
Journal:  Trends Neurosci       Date:  1992-05       Impact factor: 13.837

8.  Evidence of a preferential role of brain serotonin in the mechanisms leading to naloxone-precipitated compulsive jumping in morphine-dependent rats.

Authors:  L Cervo; C Rochat; S Romandini; R Samanin
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  Involvement of 5-hydroxytryptamine in the analgesic action of pethidine and morphine in mice.

Authors:  R Botting; A Morinan
Journal:  Br J Pharmacol       Date:  1982-04       Impact factor: 8.739

10.  Effect of alpha-fluoromethylhistidine on the histamine content of the brain of W/Wv mice devoid of mast cells: turnover of brain histamine.

Authors:  K Maeyama; T Watanabe; A Yamatodani; Y Taguchi; H Kambe; H Wada
Journal:  J Neurochem       Date:  1983-07       Impact factor: 5.372

View more
  2 in total

1.  Changes induced by sodium cromoglycate in brain catecholamine turnover in morphine dependent and abstinent mice.

Authors:  O San-Martín-Clark; B Cuéllar; J De Alba; J C Leza; P Lorenzo
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

2.  Disease-modifying effects of ganglioside GM1 in Huntington's disease models.

Authors:  Melanie Alpaugh; Danny Galleguillos; Juan Forero; Luis Carlos Morales; Sebastian W Lackey; Preeti Kar; Alba Di Pardo; Andrew Holt; Bradley J Kerr; Kathryn G Todd; Glen B Baker; Karim Fouad; Simonetta Sipione
Journal:  EMBO Mol Med       Date:  2017-11       Impact factor: 12.137

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.